Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results

Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results Completed GX-03 Stage 1/Phase 2a Trial: 59.3% of GX-03 Patients Achieved Clear or Almost Clear Skin After Four Weeks, Compared with 30.4% Receiving Vehicle Larger Phase 2b A

Event · Earnings
Original reporting
Published Nov 9, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 12:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$TTRX
Bullish
high confidence
Mentioned
$TTRX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TTRXBullishMed
01

Why it matters

The disclosed trial results and accelerated enrollment are primary disclosures that can materially affect the stock price.

02

Market read

First report of positive trial data and leadership change provides fresh catalyst for TTRX.

03

What to watch

Cash runway only to Q3 2027; additional financing may be required.

Relevance 7/10Novelty 9/10Timing: today

Background

Turn Therapeutics (Nasdaq: TTRX) is a clinical‑stage biotech focused on non‑systemic skin disease therapies.

Company-level read

Ticker impact

$TTRXBullishHigh confidence
Context

Turn Therapeutics disclosed positive Phase 1/2a trial results for GX-03 in atopic dermatitis and announced accelerated Phase 2a hidradenitis suppurativa enrollment, plus a new Chief Scientific Officer appointment.

Expected impact

likely upward pressure as investors price in promising efficacy signals and expanded pipeline.

Evidence & confidence

First disclosure of trial efficacy numbers and accelerated timelines typically moves biotech stocks on the day of release.

Market effects

Strengthens the atopic dermatitis and hidradenitis suppurativa therapeutic segments, may boost peer biotech valuations.

U.S. biotech sector sees modest lift.

Limited to specialty dermatology biotech space.

Counterpoint

Early‑stage data may not translate to later trials; investors should weigh execution risk.

Key entities

  • Turn Therapeutics Inc.

    Biotech developer of GX-03.

  • Robert R. Redfield, M.D.

    New Chief Scientific Officer, former CDC Director.

Related articles

$TTRXMed

WBB Securities upgrades Turn Therapeutics stock rating to hold

WBB Securities upgraded Turn Therapeutics (TTRX) to Hold from Sell, setting a $10.00 price target. The stock has fallen from $16.45 but is up over 200% in six months. WBB expects Phase 2 trial results in 2026, but sees challenges for small-cap life science firms. Lucid Capital Markets initiated coverage with a Buy rating and $24.00 target, citing GX-03's potential.

$TTRXMedAI 8/10

Turn updates investor presentation; Phase 2 AD topline due Q1 2027, $10.3M cash runways into Q3 2027

Turn Therapeutics updated its investor presentation, highlighting GX-03 clinical progress and a $10.3M cash balance as of June 30, 2026. The company expects Phase 2 topline results for atopic dermatitis in Q1 2027 and has a cash runway into Q3 2027. Key milestones include an FDA meeting in Q4 2026 and Phase 3 initiations in 2027. The presentation also details safety and efficacy signals, financials, and IP status.

$TTRXMed

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Low

$TTRXMed

Turn Therapeutics stock rises on expanded dermatitis trial By Investing.com

Turn Therapeutics (TTRX) shares rose 3.8% premarket after expanding its GX-03 Phase 2 atopic dermatitis trial to a broader EASI severity population. The company completed an interim analysis and said efficacy was seen in mild-to-moderate patients (EASI 1.1–7.0), with 71.4% vs 33.3% vehicle achieving Week 4 vIGA-AD success. Final design targets ~120–135 patients; no treatment-related serious AEs reported.